Arcus Biosciences, a clinical-stage biotech developing cancer immunotherapies, raised $120 million by offering 8 million shares at $15, the high end of the range of $13 to $15. Arcus Biosciences plans to list on the NYSE under the symbol RCUS. Citi, Goldman Sachs and Leerink Partners acted as lead managers on the deal.
